Browse > Article
http://dx.doi.org/10.5223/pghn.2015.18.1.39

Laboratory Markers Indicating Gastrointestinal Involvement of Henoch-Schönlein Purpura in Children  

Hong, Jeana (Department of Pediatrics, Kangwon National University Hospital, Kangwon National University School of Medicine)
Yang, Hye Ran (Department of Pediatrics, Seoul National University Bundang Hospital)
Publication Information
Pediatric Gastroenterology, Hepatology & Nutrition / v.18, no.1, 2015 , pp. 39-47 More about this Journal
Abstract
Purpose: To determine clinically useful biochemical markers reflecting disease activity and/or gastrointestinal (GI) tract involvement in Henoch-$Sch{\ddot{o}}nlein$ purpura (HSP). Methods: A total of 185 children with HSP and 130 controls were included. Laboratory data indicating inflammation, standard coagulation, and activated coagulation were analyzed for the HSP patients, including measurements of the hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelet count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, prothrombin time, activated partial thromboplastin time, and fibrinogen, D-dimer, and fibrin degradation product (FDP) levels. The clinical scores of the skin, joints, abdomen, and kidneys were assessed during the acute and convalescence phases of HSP. Results: The WBC count, ANC, ESR, and CRP, fibrinogen, D-dimer, and FDP levels were significantly higher in the acute phase compared with the convalescent phase of HSP (p<0.05). The total clinical scores were more strongly correlated with the D-dimer (r=0.371, p<0.001) and FDP (r=0.369, p<0.001) levels than with inflammatory markers, such as the WBC count (r=0.241, p=0.001), ANC (r=0.261, p<0.001), and CRP (r=0.260, p<0.001) levels. The patients with GI symptoms had significantly higher ANC (median [interquartile range], 7,138.0 [4,446.4-9,470.0] vs. 5,534.1 [3,263.0-8,153.5], p<0.05) and CRP (0.49 [0.15-1.38] vs. 0.23 [0.01-0.67], p<0.05), D-dimer (2.63 [1.20-4.09] vs. 1.75 [0.62-3.39]), and FDP (7.10 [0.01-13.65] vs. 0.10 [0.01-7.90], p<0.05) levels than those without GI symptoms. Conclusion: D-dimer and FDPs are more strongly associated with disease activity and more consistently reflect GI involvement than inflammatory markers during the acute phase of HSP.
Keywords
Purpura; $Sch{\ddot{o}}nlein$-Henoch; Blood coagulation; Inflammation; Fibrin fibrinogen degradation products; Fibrin fragment D; Child;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 1990;33: 1114-21.
2 Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006;65:936-41.
3 Kim S, Yoon J, Jeong S. Comparison of the clinical manifestations and prognosis of Henoch-Schonlein purpura in children with and without abdominal pain. Korean J Pediatr Gastroenterol Nutr 2011;14:359-67.   DOI
4 Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 2005;35:143-53.   DOI
5 Calvino MC, Llorca J, Garcia-Porrua C, Fernandez-Iglesias JL, Rodriguez-Ledo P, Gonzalez-Gay MA. Henoch-Schonlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine (Baltimore) 2001;80:279-90.   DOI
6 Hung SP, Yang YH, Lin YT, Wang LC, Lee JH, Chiang BL. Clinical manifestations and outcomes of Henoch-Schonlein purpura: comparison between adults and children. Pediatr Neonatol 2009;50:162-8.   DOI
7 Martinez-Frontanilla LA, Haase GM, Ernster JA, Bailey WC. Surgical complications in Henoch-Schonlein Purpura. J Pediatr Surg 1984;19:434-6.   DOI
8 Faille-Kuyber EH, Kater L, Kooiker CJ, Dorhout Mees EJ. IgA-deposits in cutaneous blood-vessel walls and mesangium in Henoch-Schonlein syndrome. Lancet 1973;1:892-3.
9 Besbas N, Saatci U, Ruacan S, Ozen S, Sungur A, Bakkaloglu A, et al. The role of cytokines in Henoch Schonlein purpura. Scand J Rheumatol 1997;26:456-60.   DOI
10 Claudy A. Coagulation and fibrinolysis in cutaneous vasculitis. Clin Dermatol 1999;17:615-8.
11 Ates E, Bakkaloglu A, Saatci U, Soylemezoglu O. von Willebrand factor antigen compared with other factors in vasculitic syndromes. Arch Dis Child 1994;70:40-3.   DOI
12 Hergesell O, Andrassy K, Nawroth P. Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis. Thromb Haemost 1996;75:892-8.
13 Rose PE, Struthers GS, Robertson M, Kavi J, Chant I, Taylor CM. Factor VIII von Willebrand protein in haemolytic uraemic syndrome and systemic vasculitides. Lancet 1990;335:500-2.   DOI
14 De Mattia D, Penza R, Giordano P, Del Vecchio GC, Aceto G, Altomare M, et al. von Willebrand factor and factor XIII in children with Henoch-Schonlein purpura. Pediatr Nephrol 1995;9:603-5.   DOI
15 Yang YH, Yu HH, Chiang BL. The diagnosis and classification of Henoch-Schonlein purpura: an updated review. Autoimmun Rev 2014;13:355-8.   DOI
16 Yilmaz D, Kavakli K, Ozkayin N. The elevated markers of hypercoagulability in children with Henoch-Schonlein purpura. Pediatr Hematol Oncol 2005;22:41-8.   DOI
17 Saulsbury FT. Henoch-Schonlein purpura. Curr Opin Rheumatol 2010;22:598-602.   DOI
18 Yang YH, Chuang YH, Wang LC, Huang HY, Gershwin ME, Chiang BL. The immunobiology of Henoch-Schonlein purpura. Autoimmun Rev 2008;7:179-84.   DOI
19 Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005;15:254-9.   DOI
20 Szaba FM, Smiley ST. Roles for thrombin and fibrin( ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002;99:1053-9.   DOI
21 Del Vecchio GC, Penza R, Altomare M, Piacente L, Aceto G, Lassandro G, et al. Cytokine pattern and endothelium damage markers in Henoch-Schonlein purpura. Immunopharmacol Immunotoxicol 2008;30:623-9.   DOI
22 Dalens B, Travade P, Labbe A, Bezou MJ. Diagnostic and prognostic value of fibrin stabilising factor in Schonlein-Henoch syndrome. Arch Dis Child 1983;58: 12-4.   DOI
23 Kamitsuji H, Tani K, Yasui M, Taniguchi A, Taira K, Tsukada S, et al. Activity of blood coagulation factor XIII as a prognostic indicator in patients with Henoch-Schonlein purpura. Efficacy of factor XIII substitution. Eur J Pediatr 1987;146:519-23.   DOI
24 Kang Y, Park JS, Ha YJ, Kang MI, Park HJ, Lee SW, et al. Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schonlein purpura. J Korean Med Sci 2014;29:198-203.   DOI
25 Brendel-Muller K, Hahn A, Schneppenheim R, Santer R. Laboratory signs of activated coagulation are common in Henoch-Schonlein purpura. Pediatr Nephrol 2001; 16:1084-8.   DOI